Urinary Tract Infection and Pyelonephritis (Adult)

1. Overview

Urinary Tract Infections (UTIs) represent the most common bacterial infection in adults, accounting for over 150 million cases annually worldwide. [1] The clinical spectrum ranges from uncomplicated cystitis (lower UTI) confined to the bladder, to life-threatening pyelonephritis (upper UTI) involving the renal parenchyma, and ultimately urosepsis with multi-organ dysfunction.

The distinction between lower UTI (cystitis) and upper UTI (pyelonephritis) is clinically critical as it determines treatment intensity, duration, and disposition. Lower UTI presents with bladder irritation symptoms (dysuria, frequency, urgency) without systemic features, while upper UTI manifests with flank pain, fever, and constitutional symptoms indicating renal parenchymal involvement. [2]

Equally important is the classification into uncomplicated versus complicated UTI. Uncomplicated UTI occurs in healthy, non-pregnant, premenopausal women with normal urinary tract anatomy. Complicated UTI involves any factor that increases treatment failure risk: male sex, pregnancy, diabetes, immunosuppression, urinary obstruction, catheterisation, or anatomical abnormalities. This classification drives antibiotic choice, treatment duration, and need for imaging. [3]

The management landscape has evolved significantly, with the 2024 IDSA guidelines, 2025 AUA/CUA/SUFU guideline update for recurrent UTI, and 2023 ACOG guidance for pregnancy emphasising antimicrobial stewardship, local resistance patterns, and patient-centred approaches. [4,5]

---

2. Epidemiology

Incidence and Prevalence

Risk Factor Profiles

Demographics

• Age distribution: Bimodal in women (sexually active years, post-menopause)
• Male UTI: Uncommon before age 50; increases with BPH prevalence
• Elderly: Higher morbidity, atypical presentations, increased mortality from urosepsis
• Healthcare-associated: 40% of all nosocomial infections; predominantly catheter-related [7]

---

3. Aetiology and Pathophysiology

Uropathogen Distribution

Community-Acquired UTI

Healthcare-Associated/Complicated UTI

Uropathogenic E. coli (UPEC) Virulence Factors

The success of E. coli as a uropathogen depends on specific virulence factors that enable colonisation, invasion, and immune evasion. [8,9]

The 7-Step Ascending Infection Pathway

1. Periurethral colonisation: Faecal flora colonise periurethral area; displacement of normal Lactobacillus
2. Urethral ascent: Bacteria ascend short female urethra; facilitated by sexual activity, catheterisation
3. Bladder adherence: Type 1 fimbriae bind to uroplakin receptors on urothelium
4. Intracellular bacterial communities (IBCs): UPEC invade superficial facet cells; form protective biofilm-like communities
5. Bladder inflammation: Innate immune response (TLR4 pathway); pyuria, haematuria
6. Ureteral ascent: Vesicoureteral reflux or direct ascent; P-fimbriae mediate renal binding
7. Renal parenchymal invasion: Pyelonephritis; potential bacteraemia and urosepsis

Complicated UTI: Anatomical and Functional Factors

---

4. Clinical Presentation

Lower UTI (Cystitis)

Classic Triad

1. Dysuria: Burning pain during micturition (positive predictive value 57%)
2. Frequency: Voiding small volumes more often than usual
3. Urgency: Compelling need to void; may include urge incontinence

Associated Symptoms

Key Feature: Afebrile

• Temperature less than 38°C distinguishes cystitis from pyelonephritis
• Absence of systemic symptoms (chills, rigors, malaise)

Upper UTI (Pyelonephritis)

Cardinal Features

Physical Examination

• Costovertebral angle (CVA) tenderness: Hallmark sign; elicited by percussion
• Fever with tachycardia: May indicate early sepsis
• Abdominal examination: Exclude peritonitis; assess for renal mass (abscess)

Atypical Presentations

Elderly Patients

• Delirium/acute confusion: May be sole presenting feature
• Functional decline: Falls, incontinence, decreased mobility
• Absence of fever: Blunted pyrexial response common
• CAUTION: Asymptomatic bacteriuria is highly prevalent in elderly; do NOT treat without symptoms [10]

Catheterised Patients

• New-onset fever without alternative source
• Altered urine character (blood, sediment)
• Suprapubic pain or discomfort
• Autonomic dysreflexia (spinal cord injury patients)

Pregnancy

• Asymptomatic bacteriuria progresses to pyelonephritis in 20-40% if untreated [5]
• Higher risk of sepsis, ARDS, preterm labour
• All bacteriuria in pregnancy requires treatment

---

5. Classification Systems

Anatomical Classification

Complexity Classification (EAU/IDSA)

Recurrence Classification

---

6. Investigations

Urinalysis (Dipstick)

Clinical Pearl: Nitrite requires 4+ hours in bladder; frequent voiding causes false negatives. Enterococcus, Pseudomonas, and S. saprophyticus do NOT reduce nitrite.

Urine Microscopy

Urine Culture

Indications (Culture Is NOT Needed for Uncomplicated Cystitis)

• All suspected pyelonephritis
• All complicated UTI
• Treatment failure
• Recurrent UTI
• Pregnancy
• Pre- and post-urological procedure

Interpretation Thresholds

Blood Tests

Imaging

Indications for Imaging in UTI

Imaging Findings in Complicated UTI

---

7. Differential Diagnosis

Dysuria-Dominant Presentation

Flank Pain with Fever

---

8. Management

Principles of Antibiotic Stewardship (The "Five Ds") [11]

1. Diagnosis: Confirm UTI with appropriate criteria; avoid treating asymptomatic bacteriuria
2. Drug: Choose narrowest spectrum effective agent
3. Dose: Appropriate for site and severity
4. Duration: Shortest effective course
5. De-escalation: Narrow therapy based on culture results

Uncomplicated Cystitis (First-Line Therapy)

Second-Line (Reserve for Allergies/Resistance)

Acute Uncomplicated Pyelonephritis

Outpatient Criteria (All Must Be Met)

• Haemodynamically stable
• Able to tolerate oral fluids and medications
• No significant vomiting
• Reliable follow-up available
• Not pregnant
• No obstruction or abscess suspected

Outpatient Regimens

Note: The COPY-ED study (2024) demonstrated cephalosporins are effective for outpatient pyelonephritis when fluoroquinolones are contraindicated. [12]

Inpatient Criteria

• Haemodynamic instability (sepsis criteria)
• Unable to tolerate oral intake
• Pregnancy
• Suspected obstruction/abscess
• Significant comorbidities
• Failed outpatient therapy

Complicated UTI and Pyelonephritis (Inpatient)

Add Vancomycin (15-20mg/kg IV q8-12h) if: Enterococcus suspected, prior colonisation, indwelling catheter with Gram-positive cocci

Duration: 7-14 days (shorter if source controlled and responding)

Urosepsis and Septic Shock

Obstructed Pyelonephritis (Pyonephrosis)

UROLOGICAL EMERGENCY - Antibiotics alone will NOT clear infection behind obstruction

Catheter-Associated UTI (CAUTI) [7,13]

Pregnancy

Critical Points [5]:

• Screen ALL pregnant women for asymptomatic bacteriuria at first antenatal visit (12-16 weeks)
• TREAT all bacteriuria (asymptomatic or symptomatic) - 20-40% progress to pyelonephritis if untreated
• ALL pyelonephritis in pregnancy = ADMISSION for IV antibiotics

---

9. Recurrent UTI Management

Definition

• ≥2 symptomatic UTIs in 6 months, OR
• ≥3 symptomatic UTIs in 12 months

Investigation for Structural Abnormalities [14]

Non-Antimicrobial Prevention Strategies [6,14,15]

Antimicrobial Prophylaxis [6,14]

2025 AUA/CUA/SUFU Guideline Update: Emphasises non-antibiotic strategies first; vaginal oestrogen strongly recommended for postmenopausal women; methenamine hippurate recommended before continuous antibiotic prophylaxis. [4]

---

10. Antibiotic Resistance Considerations

Global Resistance Patterns [18,19]

ESBL-Producing Enterobacteriaceae

Treatment of ESBL UTI: Carbapenems (ertapenem for UTI; meropenem for sepsis); fosfomycin for uncomplicated cystitis; nitrofurantoin if susceptible

Local Antibiogram

Always check your institution's local antibiogram before prescribing. Empiric therapy should be based on local resistance patterns, not national guidelines alone.

---

11. Complications

---

12. Prognosis

Uncomplicated Cystitis

• Resolution: > 90% with appropriate therapy
• Recurrence: 20-30% within 6 months
• Mortality: Near zero

Pyelonephritis

• Outpatient treatment success: 85-90%
• Hospitalisation mortality: less than 1% (uncomplicated); 5-10% (complicated)
• Progression to chronic pyelonephritis/CKD: Rare with appropriate treatment

Urosepsis

• Mortality: 20-40% with septic shock
• Morbidity: AKI, ARDS, prolonged ICU stay
• Long-term: Increased cardiovascular events post-sepsis

---

13. Special Populations

Men

• All UTI in men is complicated by definition
• Consider: Prostatitis, BPH, urethral stricture
• Investigations: Prostate examination, PSA if age-appropriate, post-void residual ultrasound
• Treatment duration: 7-14 days (longer for prostatitis)
• Referral: Urology for recurrent UTI

Elderly

• Atypical presentations (confusion, falls, functional decline)
• DO NOT treat asymptomatic bacteriuria - prevalence 20-50% in elderly; no benefit to treatment; harm from antibiotics [10]
• Lower threshold for admission and imaging
• Increased antibiotic resistance; review local flora

Spinal Cord Injury

• Neurogenic bladder; incomplete emptying
• Higher CAUTI rates
• Autonomic dysreflexia may be presenting sign
• Altered/absent pain sensation

Diabetic Patients

• Higher risk of complications (emphysematous pyelonephritis, abscess)
• Broader empiric coverage; lower threshold for admission
• Glucose control important for recovery

---

14. Key Guidelines

---

15. Exam-Focused Content

High-Yield Facts for Examinations

1. E. coli causes 80% of community-acquired UTI; P-fimbriae predict pyelonephritis
2. Nitrofurantoin does NOT achieve renal tissue levels - only for cystitis, NOT pyelonephritis
3. Pyonephrosis = obstructed infected kidney - antibiotics alone will fail; needs urgent drainage
4. Pregnancy: Screen and treat ALL bacteriuria; 20-40% progress to pyelonephritis if untreated
5. Asymptomatic bacteriuria: Only treat in pregnancy and pre-urology procedures
6. Fluoroquinolones: Reserve for pyelonephritis; not first-line for uncomplicated cystitis (stewardship)
7. Proteus mirabilis: Urease producer → alkaline urine → struvite stones
8. S. saprophyticus: Second commonest cause in young sexually active women
9. ESBL E. coli: Increasing; travel history important; carbapenem for serious infection
10. Emphysematous pyelonephritis: Gas on CT; mostly diabetics; high mortality; often needs nephrectomy

Common Exam Questions

1. "What organisms cause UTI and what are their distinguishing features?"
2. "Describe the management of uncomplicated cystitis vs pyelonephritis."
3. "When would you image a patient with UTI?"
4. "How would you manage recurrent UTI in a postmenopausal woman?"
5. "A pregnant woman presents with fever and flank pain - discuss your management."

Viva Opening Statement

"UTI is the most common bacterial infection in adults, caused predominantly by ascending infection with E. coli (80%). It is classified anatomically as lower (cystitis) or upper (pyelonephritis), and by complexity based on host factors. Management is stratified by severity, with uncomplicated cystitis treated with short-course oral antibiotics, while complicated UTI and pyelonephritis may require broader coverage and imaging to exclude obstruction."

Model Answer: Recurrent UTI Management

Q: A 65-year-old postmenopausal woman presents with her fourth UTI this year. How would you manage her?

A: "I would approach this systematically:

History: Confirm genuine recurrence vs treatment failure; symptom pattern; sexual activity association; voiding symptoms (incomplete emptying); fluid intake; hygiene practices; previous organisms and sensitivities.

Examination: Abdominal/pelvic examination; look for vaginal atrophy; PVR measurement.

Investigations: MSU for culture; renal/bladder ultrasound (exclude stones, PVR, structural abnormality); consider CT urogram if haematuria or suspicion of upper tract pathology.

Management:

1. Non-antimicrobial first (per 2025 AUA guidelines):

   • Vaginal oestrogen (cream or pessary) - strongly recommended; reduces recurrence by 50%
   • Increase fluid intake to 2-3L/day
   • D-mannose or cranberry products
   • Methenamine hippurate 1g BD

2. If non-antimicrobial strategies insufficient:

   • Low-dose prophylaxis: Nitrofurantoin 50-100mg nocte for 6-12 months
   • OR self-start therapy if reliable patient

3. Follow-up: Review at 3-6 months; consider urology referral if no improvement"

---

16. Single Best Answer Questions

Question 1

A 28-year-old woman presents with 2 days of dysuria and frequency. She is afebrile, has suprapubic tenderness, and urinalysis shows leukocyte esterase positive and nitrites positive. She has no drug allergies. What is the most appropriate treatment?

A) Ciprofloxacin 500mg BD for 7 days B) Nitrofurantoin 100mg BD for 5 days C) Ceftriaxone 1g IV stat then oral step-down D) Amoxicillin-clavulanate 625mg TDS for 7 days E) Trimethoprim 200mg BD for 14 days

Answer: B

This is uncomplicated cystitis (lower UTI) in a healthy premenopausal woman. Nitrofurantoin 100mg BD for 5 days is first-line therapy per IDSA guidelines. Fluoroquinolones should be reserved for pyelonephritis (antimicrobial stewardship). Ceftriaxone IV is unnecessary for uncomplicated cystitis. The 7-day and 14-day courses are unnecessarily long.

Question 2

A 45-year-old diabetic woman presents with fever 39.2°C, right flank pain, vomiting, and confusion. BP 88/52, HR 118. Urinalysis shows pyuria. CT shows right hydronephrosis with a 1.2cm obstructing ureteric stone. What is the MOST important next step?

A) IV ceftriaxone and fluids B) IV meropenem and vasopressors C) Urgent urology referral for nephrostomy/stent D) Extracorporeal shock wave lithotripsy E) CT-guided percutaneous abscess drainage

Answer: C

This is obstructed pyelonephritis (pyonephrosis) with sepsis. The KEY intervention is urgent decompression via nephrostomy or ureteral stent - antibiotics alone will NOT clear infection behind an obstruction. While antibiotics and resuscitation are essential (and should be started immediately), source control is paramount. ESWL is contraindicated in active infection.

Question 3

Which of the following patients with bacteriuria should receive antibiotic treatment?

A) 78-year-old nursing home resident with confusion and E. coli 10⁵ CFU/mL B) 30-year-old pregnant woman at 14 weeks with Group B Strep 10⁵ CFU/mL, asymptomatic C) 65-year-old man with indwelling catheter, E. coli 10⁵ CFU/mL, afebrile, no symptoms D) 82-year-old woman with dementia, cloudy urine, E. coli 10⁵ CFU/mL, afebrile E) 55-year-old diabetic woman with E. coli 10⁵ CFU/mL, no urinary symptoms

Answer: B

Asymptomatic bacteriuria should ONLY be treated in pregnancy (20-40% progress to pyelonephritis) and before urological procedures. Options A, D, and E represent asymptomatic bacteriuria in non-pregnant individuals and should NOT be treated. Option C is asymptomatic catheter-associated bacteriuria, which is extremely common and should not be treated unless symptomatic.

---

17. Additional SBA Questions

Question 4

A 52-year-old woman with type 2 diabetes presents with dysuria and frequency for 3 days. Urine dipstick shows leukocyte esterase positive and nitrite positive. She has had 4 UTIs in the past year, most recently 6 weeks ago treated with nitrofurantoin. Her eGFR is 35 mL/min/1.73m². What is the most appropriate antibiotic choice?

A) Nitrofurantoin 100mg BD for 5 days B) Trimethoprim-sulfamethoxazole DS BD for 3 days C) Fosfomycin 3g single dose D) Ciprofloxacin 250mg BD for 3 days E) Cephalexin 500mg QDS for 7 days

Answer: C

Nitrofurantoin is contraindicated when eGFR less than 30-45 mL/min due to reduced efficacy (inadequate urinary concentration) and increased peripheral neuropathy risk. Fosfomycin is a good option for recurrent UTI and achieves adequate urinary concentration even with reduced renal function. TMP-SMX could be considered but requires dose adjustment and there is a higher resistance rate with recurrent UTI. Fluoroquinolones should be reserved for pyelonephritis. Cephalexin for 7 days is less effective than other options.

Question 5

A 35-year-old pregnant woman at 28 weeks gestation presents with fever 38.8°C, right flank pain, and vomiting. She is diagnosed with pyelonephritis. Blood cultures are negative at 24 hours. She has improved clinically on IV ceftriaxone. What is the next step?

A) Discharge on oral ciprofloxacin to complete 7-day course B) Continue IV antibiotics for 14 days C) Switch to oral amoxicillin-clavulanate to complete 7-10 days D) Discharge without further antibiotics as cultures negative E) Switch to oral trimethoprim to complete 14 days

Answer: C

In pregnancy, fluoroquinolones (ciprofloxacin) are contraindicated due to cartilage toxicity. Trimethoprim should be avoided, particularly in the first trimester (folate antagonist) but also generally avoided throughout pregnancy. The patient has improved on IV ceftriaxone; oral step-down to a safe agent like amoxicillin-clavulanate or cephalexin is appropriate. Blood cultures being negative does not mean treatment should stop. Total duration of 7-10 days for pyelonephritis is standard.

Question 6

A 70-year-old man with BPH presents with urinary frequency and hesitancy for 2 weeks. He is afebrile with suprapubic tenderness. Urinalysis shows pyuria and bacteriuria. Post-void residual volume is 180mL. Which statement regarding his management is CORRECT?

A) Treat as uncomplicated cystitis with nitrofurantoin for 5 days B) UTI in men is always complicated; treat for 7-14 days and investigate C) Obtain urine culture but treat empirically with fosfomycin single dose D) Prostatic massage should be performed to rule out prostatitis E) Imaging is not required if he responds to antibiotics

Answer: B

All UTI in men is by definition "complicated" due to anatomical factors. Treatment duration should be 7-14 days (longer if prostatitis suspected). Investigation for underlying cause (BPH, stones, stricture) is indicated. Prostatic massage is contraindicated in acute prostatitis (risk of bacteraemia). Fosfomycin single dose has limited penetration to prostate and is not recommended for male UTI. Imaging (ultrasound with post-void residual) is appropriate given his voiding symptoms and elevated PVR.

Question 7

Which finding on CT imaging most strongly indicates need for urgent surgical intervention in a patient with pyelonephritis?

A) Focal renal enlargement with striated nephrogram B) Perinephric fat stranding C) Gas within the renal parenchyma D) Small non-obstructing renal calculus E) Thickening of renal pelvis

Answer: C

Gas within the renal parenchyma indicates emphysematous pyelonephritis - a severe, necrotising infection predominantly seen in diabetics. This has high mortality (20-40%) and often requires nephrectomy or aggressive percutaneous drainage. The other findings (striated nephrogram, perinephric fat stranding, pelvic thickening) are common in uncomplicated pyelonephritis and typically respond to antibiotic therapy alone. A non-obstructing stone does not require urgent intervention.

Question 8

A 28-year-old woman has had 5 UTIs in the past 8 months, all caused by different E. coli strains. Her renal ultrasound is normal. She has tried cranberry supplements without benefit. According to the 2025 AUA/CUA/SUFU guidelines, which intervention has the STRONGEST recommendation before initiating continuous antibiotic prophylaxis?

A) D-mannose supplementation B) Vaginal oestrogen therapy C) Methenamine hippurate D) Lactobacillus probiotics E) Increased fluid intake

Answer: C

The 2025 AUA/CUA/SUFU guideline update specifically recommends methenamine hippurate as a non-antibiotic strategy before moving to continuous antibiotic prophylaxis. Vaginal oestrogen is strongly recommended for POSTMENOPAUSAL women, but this patient is premenopausal. D-mannose has emerging evidence but is rated lower than methenamine. Probiotics and increased fluids have weaker evidence. For premenopausal women, methenamine hippurate (1g BD) is preferred before long-term antibiotics.

---

18. Advanced Pathophysiology

Intracellular Bacterial Communities (IBCs)

A critical discovery in UTI pathogenesis is the ability of UPEC to invade superficial bladder epithelial cells and form intracellular bacterial communities (IBCs). [21] This represents a bacterial survival strategy with major clinical implications:

This mechanism explains why some women experience recurrent UTI despite appropriate antibiotic therapy - bacteria hiding within bladder epithelial cells are protected from both antibiotics and the immune system. Novel therapies targeting IBC disruption are under investigation.

Host Genetic Susceptibility

Genetic polymorphisms influence UTI susceptibility: [22]

The Vaginal Microbiome and UTI

The urogenital microbiome paradigm has shifted understanding of UTI pathogenesis. Lactobacillus-dominant vaginal flora provides colonisation resistance against uropathogens: [23]

Factors disrupting this protective microbiome include:

• Antibiotic use (especially broad-spectrum)
• Spermicides (especially nonoxynol-9)
• Postmenopausal oestrogen decline
• Douching
• Sexual intercourse

---

19. Emerging Therapies and Future Directions

Novel Antimicrobial Agents

Non-Antimicrobial Approaches Under Investigation

Precision Medicine in UTI

Emerging approaches include:

• Point-of-care molecular diagnostics: Rapid pathogen identification and resistance detection
• Microbiome-based interventions: Vaginal Lactobacillus transplantation
• Biomarker-guided therapy: Procalcitonin to distinguish upper from lower UTI
• AI-assisted antibiogram prediction: Machine learning for empiric therapy selection

---

20. Quality Improvement and CAUTI Prevention

Evidence-Based CAUTI Prevention Bundle [7,13]

Catheter Removal Criteria (Nurse-Driven Protocol) [24]

Automatic catheter removal unless documented medical indication:

• Post-operative urological/gynaecological procedure
• Acute urinary retention (with void trial planned)
• Accurate output monitoring in critically ill (with daily reassessment)
• End-of-life comfort care
• Severe skin wounds (perineal/sacral requiring protection)

---

21. Clinical Decision Algorithms

Algorithm 1: Approach to Suspected UTI in Women

Dysuria + Frequency/Urgency
        ↓
   Afebrile? ────────No──────→ Consider pyelonephritis
        ↓                       (fever, flank pain)
       Yes                      → Blood tests, cultures, imaging PRN
        ↓
Vaginal discharge/irritation?
        ↓
       Yes ─────────────────→ Pelvic exam; consider STI/vaginitis
        ↓
       No
        ↓
   Classic UTI symptoms in healthy premenopausal woman
        ↓
   Uncomplicated? ────No────→ Complicated UTI
   (no risk factors)           → Urine culture
        ↓                      → Broader coverage
       Yes                     → 7-14 day treatment
        ↓
   Treat empirically
   - Nitrofurantoin 100mg BD x 5 days (first-line)
   - Or TMP-SMX if local resistance less than 20%
   - Or Fosfomycin 3g single dose
        ↓
   Symptoms persisting > 48h?
        ↓
       Yes ─────────────────→ Obtain culture; reassess; consider pyelonephritis
        ↓
       No → Treatment success

Algorithm 2: Imaging Decision in UTI

Suspected/Confirmed UTI
        ↓
Uncomplicated cystitis? ───Yes───→ No imaging needed
        ↓
       No
        ↓
Complicated UTI or Pyelonephritis
        ↓
Clinical response to antibiotics?
        ↓
   Good response by 48-72h ────→ Usually no imaging unless:
        ↓                        - Recurrent pyelonephritis
       No                        - History suggesting structural abnormality
        ↓
   Imaging indicated
        ↓
Pregnant? ───Yes───→ Ultrasound (avoid radiation)
        ↓
       No
        ↓
   CT abdomen/pelvis (± contrast based on renal function)
        ↓
   Look for: Obstruction, abscess, emphysematous changes, stone

---

22. Medico-Legal Considerations

Documentation Requirements

Common Medico-Legal Pitfalls

---

23. Patient Education

Condition Explanation

"You have a urinary tract infection - bacteria have entered your bladder/kidneys and caused an infection. This is very common, especially in women. We'll treat this with antibiotics to clear the infection."

Medication Instructions

• Complete the full course of antibiotics even if you feel better
• Take with food if stomach upset occurs
• Nitrofurantoin should be taken with food for best absorption

Prevention Strategies

• Drink plenty of fluids (2-3 litres per day)
• Urinate frequently; don't "hold on"
• Urinate after sexual intercourse
• Wipe front to back
• Avoid spermicides if prone to UTI
• Consider cranberry products (though evidence is modest)

When to Return

• Fever, chills, or worsening flank pain
• Unable to keep fluids or medications down
• Symptoms not improving after 48 hours of treatment
• Blood in urine persisting after treatment
• New confusion or drowsiness (especially in elderly)

---

18. References

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S-13S. doi:10.1016/s0002-9343(02)01054-9

2. Al Lawati H, et al. Urinary Tract Infections: Core Curriculum 2024. Am J Kidney Dis. 2024;83(2):254-264. doi:10.1053/j.ajkd.2023.08.009

3. Gupta K, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257

4. Ackerman AL, et al. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2025. doi:10.1097/JU.0000000000004723

5. ACOG Committee Opinion. Urinary Tract Infections in Pregnant Individuals. Obstet Gynecol. 2023;142(2):435-445. doi:10.1097/AOG.0000000000005269

6. Peck RN, et al. Recurrent Urinary Tract Infections: Diagnosis, Treatment, and Prevention. Obstet Gynecol Clin North Am. 2021;48(3):501-513. doi:10.1016/j.ogc.2021.05.005

7. Patel PK, et al. Strategies to prevent catheter-associated urinary tract infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(8):1209-1231. doi:10.1017/ice.2023.137

8. Bunduki GK, et al. Virulence factors and antimicrobial resistance of uropathogenic Escherichia coli (UPEC) isolated from urinary tract infections: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):753. doi:10.1186/s12879-021-06435-7

9. Gebremedhin S, et al. The role of uropathogenic Escherichia coli virulence factors in the development of urinary tract infection. J Med Life. 2025;18(2):123-132. doi:10.25122/jml-2024-0396

10. Nicolle LE, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121

11. Goebel MC, et al. The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. Clin Microbiol Rev. 2021;34(4):e00003-20. doi:10.1128/CMR.00003-20

12. Koehl JL, et al. Cephalosporins for Outpatient Pyelonephritis in the Emergency Department: COPY-ED Study. Ann Emerg Med. 2024. doi:10.1016/j.annemergmed.2024.10.013

13. Van Decker SG, et al. Catheter-associated urinary tract infection reduction in critical care units: a bundled care model. BMJ Open Qual. 2021;10(4):e001534. doi:10.1136/bmjoq-2021-001534

14. Alghoraibi M, et al. Recurrent Urinary Tract Infection in Adult Patients, Risk Factors, and Efficacy of Low Dose Prophylactic Antibiotics Therapy. J Epidemiol Glob Health. 2023;13(2):251-259. doi:10.1007/s44197-023-00105-4

15. Lenger SM, et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265.e1-265.e13. doi:10.1016/j.ajog.2020.05.048

16. Xia JY, et al. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One. 2021;16(9):e0256992. doi:10.1371/journal.pone.0256992

17. Cooper TE, et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev. 2022;8(8):CD013608. doi:10.1002/14651858.CD013608.pub2

18. Naber KG, et al. Therapeutic strategies for uncomplicated cystitis in women. GMS Infect Dis. 2024;12:Doc02. doi:10.3205/id000086

19. Curtis LT, et al. Resistance to first-line antibiotic therapy among patients with uncomplicated acute cystitis in Melbourne, Australia: prevalence, predictors and clinical impact. JAC Antimicrob Resist. 2023;5(6):dlad145. doi:10.1093/jacamr/dlad145

20. Kurotschka PK, et al. Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. Am Fam Physician. 2024;109(2):156-162.

21. Anderson GG, et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science. 2003;301(5629):105-107. doi:10.1126/science.1084550

22. Scholes D, et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005;142(1):20-27. doi:10.7326/0003-4819-142-1-200501040-00008

23. Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr. 2016;4(6):UTI-0025-2016. doi:10.1128/microbiolspec.UTI-0025-2016

24. Tyson AF, et al. Implementation of a Nurse-Driven Protocol for Catheter Removal to Decrease Catheter-Associated Urinary Tract Infection Rate in a Surgical Trauma ICU. J Intensive Care Med. 2020;35(7):738-744. doi:10.1177/0885066618781304

25. Bader MS, et al. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020;132(3):234-250. doi:10.1080/00325481.2019.1680052

26. Wagenlehner FME, et al. Diagnosis and management for urosepsis. Int J Urol. 2013;20(10):963-970. doi:10.1111/iju.12200

---

Appendix: Quick Reference Cards

Card 1: Antibiotic Selection for UTI

Card 2: Red Flags Requiring Urgent Action

Card 3: When NOT to Treat Bacteriuria

EXCEPTIONS (Treat Asymptomatic Bacteriuria):

• Pregnancy (ALL trimesters)
• Before urological procedures that breach mucosa

---

Last Updated: 2026-01-09 | MedVellum Editorial Team Topic: 820/1071